logo-loader
viewPendragon Group

Pendragon Group raises profit expectations

car_sale_350_526e7c4b83179.jpg

A trading statement from Pendragon (LON:PDG) reinforced the notion that Britain's car dealers are among the first to enjoy the fruits of an economic recovery.

The group raised full-year profit expectations after the second half of the year saw a continuation of the profit performance improvement seen in the first half.

The group said the improved performance is due to a combination of the strategic initiatives which it has embedded in the business, as well as improved market conditions.

The latter ties in with anecdotal evidence; digital marketing specialist dotDigital (LON:DOTD) recently revealed in an analysts' briefing that it is seeing a sharp increase in marketing activity from car dealers and estate agents.

Pendragon's shares were up 3.6% in mid-afternoon trading at 39.87p, having hit 41.75p earlier in the day.

Smaller rival Caffyns (LON:CFYN) was doing better still, up 9.2% at 474.9p.

Pendragon was not getting too carried away, however; it said: "Whilst the outlook to next year remains promising, we expect that after-sales recovery, driven by new car sales, will continue to be modest and the used car market will remain broadly flat."

Quick facts: Pendragon Group

Price: 9.88 GBX

LSE:PDG
Market: LSE
Market Cap: £138.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement

SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with...

49 minutes ago

2 min read